Request Demo
Last update 13 Jun 2025
Apocyanin
Last update 13 Jun 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Acetovanillone, apocynin |
Target |
Action inhibitors |
Mechanism NOX inhibitors(NADPH oxidase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC9H10O3 |
InChIKeyDFYRUELUNQRZTB-UHFFFAOYSA-N |
CAS Registry498-02-2 |
Related
7
Clinical Trials associated with ApocyaninCTIS2023-508791-11-00
A placebo-controlled, double-blinded, randomized, dose-finding trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis
IRCT20200418047122N1
Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection: A Clinical Trial
NCT03680404
The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction
100 Clinical Results associated with Apocyanin
Login to view more data
100 Translational Medicine associated with Apocyanin
Login to view more data
100 Patents (Medical) associated with Apocyanin
Login to view more data
6,974
Literatures (Medical) associated with Apocyanin01 Sep 2025SEPARATION AND PURIFICATION TECHNOLOGY
Ni-substituted POM@UIO-66 catalyst for high-efficiency catalytic conversion of larch lignin
Author: Zhang, Dan ; Shi, Junyou ; Liu, Yuting ; Xu, Wenbiao ; Deng, Haoyu ; Li, Xiangyu
Converting abundant lignin resources into high-value chems. has always been a pivotal approach in biomass refining.Among various methods, catalytic oxidative depolymerization stands out as one of the most promising approaches due to its mild reaction conditions and remarkable efficiency.In this study, we present a series of transition metal-substituted Ni/Co-PMo/PW@UIO-66 catalysts, among which NiPMo@UIO-66 demonstrated the superior catalytic performance after thorough characterization.Through more in-depth research, it was found that under the optimal reaction conditions of 160 °C, 1.0 MPa O2, and 3 h, the strong Bronsted acidity inherent in POM, combined with the excellent redox properties, the moderate Lewis acidity provided by Ni and Zr, and the improved substrate-catalyst interfacial contact offered by the UIO-66 carrier, synergistically yielded the formation of the high amount of primary products and outstanding selectivity (>90 %).Therefore, the optimal yields of vanillin and Me vanillate reached 11.26 wt%.In terms of stability, the POM undergoes partial decomposition after multiple uses, while the UIO-66 framework maintains remarkable stability.This study aims to provide insightful and inspiring contributions to the design of catalysts within the lignin catalytic oxidative valorization system.
01 Sep 2025TOXICOLOGY AND APPLIED PHARMACOLOGY
Integrating phosphoproteome and proteome to reveal key processes through which apocynin protects from lethal ventricular arrhythmias-sudden cardiac death in early myocardial ischemia
Article
Author: Lai, Minchao ; Wang, Dian ; Liang, Huishan ; Xiao, Xudong ; Zhang, Wei ; Lv, Junyao ; Zhang, Ye ; Zhou, Danya ; Yu, Xiaojun ; Zhu, Guanghui ; Zhang, Xiaojun ; Zhang, Mengxuan
The specific role of NADPH oxidases (NOX)-dependent reactive oxygen species (X-ROS) in the development of lethal ventricular arrhythmias (LVA)-sudden cardiac death (SCD) during the early stage of myocardial ischemia (MI) remains poorly understood. Herein, we investigated the impact of X-ROS on LVA-SCD in early MI. The mouse model of MI-induced LVA-SCD and the apocynin (a NOX inhibitor)-pretreated control groups were established. Survival and the electrophysiological parameters were analyzed, and mitochondrial membrane potential (MMP), superoxide dismutase (SOD) activity, ratio of reduced and oxidized glutathione (GSH/GSSG), and ROS and Ca2+ levels were assessed. Additionally, cardiac phosphoproteome and proteome analyses were conducted to explore the phosphorylation-related mechanisms by which apocynin protects against LVA-SCD. Our findings revealed that apocynin reduced the incidence of LVA-SCD in early MI and corrected the ECG alterations associated with LVA. Apocynin also mitigated elevated levels of ROS and Ca2+ both in mitochondria and cytosol, and decreased GSH/GSSG ratio, SOD activity, and MMP in SCD. After adjusting for proteome data, 548 proteins showed significant changes in their phosphorylation levels in SCD mice. The up-regulated phosphorylated proteins normalized by apocynin were mainly linked to the tricarboxylic acid cycle (TCA), electron transport chain (ETC) function, and calcium signal pathways. The down-regulated phosphorylated proteins normalized by apocynin were mainly relevant to arrhythmogenic right ventricular cardiomyopathy and AMPK signaling pathway. Collectively, our data suggest that X-ROS promotes LVA-SCD in early MI, with Ca2+ imbalance and mitochondrial dysfunction, primarily mediated by phosphorylation changes in mitochondrial proteins, playing a crucial role.
01 Aug 2025JOURNAL OF MOLECULAR STRUCTURE
Synthesis, structural characterization, and potential antifungal activity of schiff base probes: A molecular docking study
Author: Gupta, Sofia ; Jyoti ; Kaur, Harshbir ; Dalal, Anurag ; Khurana, Sumesh ; Kaur, Amarjit ; Komal ; Malik, Sudha ; Singh, Gurjaspreet
This study focuses on the design, synthesis, and evaluation of nine new Schiff bases derived from a condensation reaction between 4-amino-1,2,4-triazol-3-one and diverse aldehyde derivativesThese compounds were synthesized through an efficient and straightforward protocol, yielding high-purity products.Comprehensive characterization was performed using 1H and 13C NMR spectroscopy, elemental anal., and mass spectrometry to confirm the mol. structures.Addnl., single-crystal X-ray diffraction anal. elucidated the detailed structures of three representative compoundsThe antifungal potential of the synthesized Schiff bases was investigated via mol. docking studies against the fungal protein target (PDB ID: 2RKT).The docking results revealed binding energies ranging from -5.87 kcal/mol to -8.37 kcal/mol, highlighting significant variations in ligand-protein affinity.Notably, two compounds demonstrated the highest potential antifungal activity, attributed to their unique structural features, such as the presence of a sulfur atom and cyclohexane moiety, resp.These findings suggest that the synthesized Schiff bases exhibit promising inhibitory potential and could serve as candidates for developing new antifungal therapies.
2
News (Medical) associated with Apocyanin16 Jan 2024
Clinical ResultPhase 2Phase 1
100 Deals associated with Apocyanin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pulmonary Disease, Chronic Obstructive | Phase 1 | - | 01 Oct 2010 | |
| Asthma | Phase 1 | Poland | 01 Jun 2008 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | salntsnbqa(fytzuffdrs) = ifcwuoxqsk ajgbksknjo (pqujzqbtmw ) | Positive | 05 Jun 2024 | ||
uushziavhn(lmsxeynbvg) = brojdykayt oxxbbpchpj (gjvzheemwq ) View more | |||||||
Not Applicable | - | Apocynin and paeonol (APPA) | gfwisbhkgn(sfrkgszvkl) = zakrhqsiqh kzeqpfqief (eqkfrwkwnh ) | Positive | 03 Jun 2020 | ||
Not Applicable | - | - | AN-1 | roynuuxgra(vqdyscolty) = rttezejcbz hflglqhauu (wguvfkopon ) View more | - | 30 Jul 2013 | |
roynuuxgra(vqdyscolty) = qcoijgjiqg hflglqhauu (wguvfkopon ) View more | |||||||
Not Applicable | Hypertension reactive oxygen species (ROS) | - | weytwirsiy(lbnhjvvvdz) = albwzuvqsu gyussxnpxd (ntwmwbgpco ) View more | Positive | 01 Sep 2012 | ||
weytwirsiy(lbnhjvvvdz) = saydsnlwmc gyussxnpxd (ntwmwbgpco ) | |||||||
Not Applicable | 14 | aotgehhnjo(kqseuwcgcx) = jaocclllpg dtgbdtupmu (uabutgwvht ) View more | Positive | 01 Sep 2011 | |||
Placebo | aotgehhnjo(kqseuwcgcx) = qqabaihzjb dtgbdtupmu (uabutgwvht ) View more | ||||||
Not Applicable | - | - | iyzxjnopgd(qxrixowlka) = iezqqtpibl bafzeuvemv (ztoflpipky ) View more | - | 01 Sep 2011 | ||
Not Applicable | - | - | uoqxrsthrf(daucouvdon) = epjmyyxwxi hrbugqoatz (cnuhjtvnqa ) View more | - | 01 Sep 2011 | ||
Placebo | uoqxrsthrf(daucouvdon) = avhoysijbd hrbugqoatz (cnuhjtvnqa ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free